Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC) frequently metastasizes to the bone, often resulting in painful skeletal events, reduced quality of life, and reduced survival. The beta-emitting radiopharmaceuticals strontium-89 and samarium-153 alleviated pain in mCRPC patients with widespre...

Descripción completa

Detalles Bibliográficos
Autor principal: Nilsson, Sten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715854/
https://www.ncbi.nlm.nih.gov/pubmed/26779616
http://dx.doi.org/10.1007/s11912-015-0495-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715854/
https://www.ncbi.nlm.nih.gov/pubmed/26779616
http://dx.doi.org/10.1007/s11912-015-0495-4

Ejemplares similares